InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Explore the full record of transactions filed by Hamed Kamal. Director active across 1 company, notably Spero Therapeutics, Inc.. Aggregated, 5 reports have been logged. Split: 0 buy · 1 sell. Total volume traded: €47k. History available since 12 September 2022. The latest transaction was disclosed on 1 February 2024 (Attribution). Regulator: SEC (Form 4). The full history is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 of 5 declarations
HAMED KAMAL is an insider linked to Spero Therapeutics, Inc., where he is Chief Medical Officer. He has 5 filings in total, and across the 5 recent filings available, sales amount to EUR 46729 and the period runs from 2022-09-14 to 2024-02-05, with a transaction nature of Attribution.